A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

Trial Profile

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Azilsartan (Primary)
  • Indications Carotid stenosis; Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ALIVE
  • Sponsors Takeda
  • Most Recent Events

    • 20 May 2016 Status changed from recruiting to discontinued.
    • 29 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
    • 29 Feb 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top